Advanced Search
Submit Manuscript Volume 32, No 10, Oct 2022
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 32 Issue 10, October 2022: 949-952
Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates
Yi Wu1,2,† , Yanqiong Shen2,† , Namei Wu1,2,† , Xinghai Zhang3,† , Shaohong Chen3,4 , Chang Yang1,2 , Junhui Zhou3,4 , Yan Wu3 , Da Chen5 , Li Wang2 , Chao Wang5 , Huajun Zhang3,* , Ninuo Xia2,* , Sandra Chiu2,* , Yucai Wang1,2,6,*
1Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDear Editor,
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 400 million people globally, resulting in millions of deaths.1 As the virus evolves, a new variant, designated as “Omicron” by the World Health Organization (SARS-CoV-2 variant B.1.1.529), has led to a massive resurgence of COVID-19 cases in many regions.2 The Omicron variant is highly contagious, with a significant transmission advantage compared to prior variants. Currently, Omicron represents ~95% of the new infections in the US, Europe, Brazil, South Africa, and elsewhere.3,4,5
https://doi.org/10.1038/s41422-022-00706-x